Several analysts have recently updated their ratings and price targets for Zentalis Pharmaceuticals (NASDAQ: ZNTL):
- 6/20/2024 – Zentalis Pharmaceuticals was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $5.00 price target on the stock, down previously from $28.00.
- 6/18/2024 – Zentalis Pharmaceuticals was downgraded by analysts at Wedbush from a “neutral” rating to an “underperform” rating. They now have a $4.00 price target on the stock, down previously from $15.00.
- 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $25.00. They now have an “outperform” rating on the stock.
- 6/18/2024 – Zentalis Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $6.00 price target on the stock, down previously from $42.00.
- 6/18/2024 – Zentalis Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $8.00 price target on the stock, down previously from $38.00.
- 6/18/2024 – Zentalis Pharmaceuticals was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $9.00 price target on the stock, down previously from $29.00.
- 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $40.00 to $20.00. They now have a “buy” rating on the stock.
- 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $32.00 to $10.00. They now have a “buy” rating on the stock.
- 5/8/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $46.00 to $40.00. They now have a “buy” rating on the stock.
- 5/8/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. They now have a “buy” rating on the stock.
Zentalis Pharmaceuticals Trading Down 14.8 %
Shares of NASDAQ ZNTL traded down $0.62 during mid-day trading on Tuesday, reaching $3.57. The company had a trading volume of 1,296,949 shares, compared to its average volume of 1,069,719. The firm has a 50 day simple moving average of $9.95 and a two-hundred day simple moving average of $12.54. The stock has a market cap of $253.58 million, a P/E ratio of -1.07 and a beta of 1.71. Zentalis Pharmaceuticals, Inc. has a 52-week low of $3.43 and a 52-week high of $29.04.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter in the prior year, the company earned ($1.07) EPS. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.72 EPS for the current year.
Insider Transactions at Zentalis Pharmaceuticals
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC lifted its position in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after purchasing an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth $156,000.
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Articles
- Five stocks we like better than Zentalis Pharmaceuticals
- 3 Monster Growth Stocks to Buy Now
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividend Challengers?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is the Shanghai Stock Exchange Composite Index?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Zentalis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.